25 February 2015
Epic Sciences announced today the appointment of Chris Bernard as chief commercial officer. Mr. Bernard has more than 20 years of experience as a senior executive and company officer leading sales and marketing teams to build biopharma and translational research partnerships and commercialize IVD platforms.
24 February 2015
Epic Sciences announced today that results from studies in metastatic castration resistant prostate cancer (mCRPC), neuroendocrine prostate cancer (NEPC) and muscle-invasive, metastatic bladder cancers using Epic's circulating tumor cell (CTC) technology will be presented at the 2015 ASCO Genitourinary Cancers Symposium which will be held February 26 to 28 at Rosen Shingle Creek in Orlando, Fla.
19 February 2015
Initially planned for a 2011 launch, Atlas Genetics' multiplex, molecular diagnostics system, called io, will hit the market four years later if the company is successful in launching it this year.
18 February 2015
A bull market doesn’t guarantee a successful IPO. Syndax Pharmaceuticals of Waltham, MA, for instance, began preparing for an IPO back nearly a year ago, but it never made its Nasdaq debut.
12 February 2015
The story of Marinus Pharmaceuticals, a biophamraceutical company developing new treatments for epilepsy and other neuropsychiatric disorders. The market for epilepsy treatments is estimated at more than $14 billion. Marinus is initially targeting a $4 billion subset of that market: patients with seizures who don't respond or are no longer responding to other medications in the market.
03 February 2015
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, announced that it has initiated a Phase 2 clinical trial with ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, in female children with epilepsy caused by a mutation of the protocadherin 19 gene (PCDH19). PCDH19 female pediatric epilepsy is a rare disease that is estimated to affect approximately 15,000-30,000 females in the U.S. and is characterized by onset of cluster seizures before age 5, cognitive and sensory impairment of varying degrees, and behavioral disturbances.
02 February 2015
Global Markets Direct's, 'NovaDigm Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the NovaDigm Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of NovaDigm Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
29 January 2015
Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces the completion of a Series C financing, raising $20 million from a syndicate including existing investors and one new investor, RMI Partners. New investor, RMI Partners, is a global life sciences venture capital firm, the largest in Eastern Europe. Existing investors include Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation - JJDC, Inc., LSP, BB Biotech Ventures and South West Ventures Fund. This newly announced financing follows on from the previously announced Series B fundraising of $25 million.
13 January 2015
Grappling with one of the world’s deadliest contagions for more than a decade without a breakthrough, the country’s leading infectious disease researchers have high hopes for a vaccine developed locally.
08 January 2015
Epic Sciences announced today that the company has received certification under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the U.S. Department of Health and Human Services’ (HHS) Center for Medicare and Medicaid Services (CMS), the state of California has granted the company’s initial CLIA clinical laboratory license.
03 July 2020
03 July 2020
02 July 2020
02 July 2020